Alpha Cognition Inc. Advances Alzheimer's Treatment with ZUNVEYL, Secures Key Regulatory Milestones
Alpha Cognition Inc. reports significant progress in the commercialization of ZUNVEYL for Alzheimer's disease, highlighting early adoption in the U.S. long-term care market and a key regulatory achievement in China.
Alpha Cognition Inc. (NASDAQ: ACOG) has made notable strides in the second quarter of 2025 with the commercialization of ZUNVEYL®, its treatment for Alzheimer's disease, marking a significant milestone in the fight against this debilitating condition. The company reported early adoption in the U.S. long-term care (LTC) market and secured a pivotal regulatory milestone in China, underscoring the global potential of ZUNVEYL.
By the end of the quarter, ZUNVEYL had been ordered in over 300 LTC facilities across priority regions, with 65% of these facilities placing repeat orders. This level of adoption signals strong clinical confidence and operational fit, as the sales team engaged more than 3,700 healthcare professionals, generating both new and repeat prescriptions. Clinician feedback has been positive, with many highlighting the cognitive and behavioral benefits of ZUNVEYL alongside its favorable tolerability profile.
A significant achievement for Alpha Cognition was securing its first national Medicare Part D contract, which requires no prior authorization, thereby enhancing patient access ahead of schedule. This development is particularly important given that Alzheimer's disease affects 7 million Americans, with over 11 million prescriptions written annually. However, more than half of patients discontinue treatment within a year due to side effects, highlighting the need for treatments like ZUNVEYL that offer both efficacy and tolerability.
The initial focus for ZUNVEYL is the LTC market, which represents 36% of Alzheimer's disease prescriptions, amounting to approximately $2 billion. The achievement of Medicare coverage shortly after launch addresses a critical barrier to access for a significant portion of the patient population and supports the company's goal of capturing market share. Additionally, Alpha Cognition anticipates generating revenues abroad in fiscal year 2026, opening a new market for its innovative treatment.
Financially, Alpha Cognition reported $1.6 million in net product sales from ZUNVEYL in the second quarter of 2025, bringing year-to-date net product revenue to approximately $2.0 million. Licensing revenue totaled $0.08 million from the CMS partnership. The company's early utilization trends, including high repeat-order rates and growing formulary wins, support management's expectation for continued adoption momentum into the second half of 2025.
On the research and development front, Alpha Cognition completed a Department of Defense-funded Bomb Blast pre-clinical study of ALPHA-1062 in a repetitive mild traumatic brain injury model. The results showed reductions in neuroinflammation and neuropathology, promising developments for patients with traumatic brain injuries. Work on a sublingual ALPHA-1062 formulation for patients with dysphagia or aphasia remains on track, with formulation completion and taste testing expected in the first quarter of 2026.
Alpha Cognition ended the quarter with $39.4 million in cash and equivalents, providing approximately two years of runway at current burn rates. The company has adjusted its 2025 operating expenses expectations to $34–38 million, down from prior guidance, through cost optimization efforts. A discounted cash flow (DCF) analysis suggests a valuation range for Alpha Cognition of $32.69 to $43.65, with a mid-point of $37.49, reflecting the company's growth potential and the significant market opportunity for ZUNVEYL.